ATNM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ATNM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Actinium Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.56 Mil. Actinium Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $1.15 Mil. Actinium Pharmaceuticals's annualized EBITDA for the quarter that ended in Sep. 2024 was $-49.60 Mil. Actinium Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was -0.03.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for Actinium Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest Debt-to-EBITDA Ratio of Actinium Pharmaceuticals was -0.01. The lowest was -0.08. And the median was -0.02.
The historical data trend for Actinium Pharmaceuticals's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Actinium Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Debt-to-EBITDA | Get a 7-Day Free Trial |
![]() |
![]() |
-0.07 | -0.03 | -0.01 | -0.08 | -0.04 |
Actinium Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Debt-to-EBITDA | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-0.04 | -0.05 | -0.05 | -0.04 | -0.03 |
For the Biotechnology subindustry, Actinium Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Actinium Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Actinium Pharmaceuticals's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Actinium Pharmaceuticals's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (0.541 | + | 1.572) | / | -51.13 | |
= | -0.04 |
Actinium Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (0.56 | + | 1.151) | / | -49.596 | |
= | -0.03 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.
Actinium Pharmaceuticals (AMEX:ATNM) Debt-to-EBITDA Explanation
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
Be Aware
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of Actinium Pharmaceuticals's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Sandesh Seth | director | 300 E 93RD STREET, #20-B, NEW YORK NY 10128 |
Steve O'loughlin | officer: VP, Finance and Corporate Dev. | 955 HARTMAN RUN ROAD, MORGANTOWN WV 26507 |
Dale L. Ludwig | officer: Chief Scientific Officer | 21 FERNWOOD ROAD, ROCKAWAY NJ 07866-2028 |
Jeffrey W. Chell | director | 521 MANDALAY AVENUE #708, CLEARWATER BEACH FL 33767 |
Ajit Shetty | director | 643 ZEEDIJK, KNOKKE C9 8300 |
Anil Kapur | officer: Chief Commercial Officer | 275 MADISON AVE, SUITE 702, NEW YORK NY 10016 |
Nitya G. Ray | officer: Executive Vice President | 14 BAYBURY COURT, EAST HANOVER NJ 07936 |
Mark Stanley Berger | officer: Chief Medical Officer | 140 RIVERSIDE DRIVE, APT. 9K, NEW YORK NY 10024 |
Memorial Sloan-kettering Cancer Center | 10 percent owner | 1275 YORK AVE., NEW YORK NY 10065 |
Sergio Traversa | director | 138 CANTERBURY LN, BLUE BELL PA 19422 |
C. David Nicholson, | director | 103 CHILDS ROAD, BASKIN RIDGE NJ 07092 |
Kaushik J Dave | director, officer: President and CEO | 4 WATER STREET, EDISON NJ 08820 |
Richard I Steinhart | director | 125 ELM STREET, NEW CANAAN CT 06840 |
Ahlb Holdings, Llc | 10 percent owner | C/O MSKCC, 1275 YORK AVE., NEW YORK NY 10065 |
Actinium Holdings, Ltd. | 10 percent owner | C/O /O STERLING MANAGEMENT, LTD., P.O. BOX HM 29, HAMILTON HM CX D0 00000 |
From GuruFocus
By PRNewswire • 11-04-2024
By PRNewswire • 08-08-2024
By PRNewswire • 03-11-2024
By PRNewswire • 06-11-2024
By GuruFocus News • 11-05-2024
By PRNewswire • 08-05-2024
By PRNewswire • 07-25-2024
By PRNewswire • 09-04-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.